drugset / Trial / NCT00442546

Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement

NCT00442546 ↗

Phase 3 Completed 307 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Pregabalin added to the standard of care with dosing starting preoperatively and continuing for up to 6 weeks post surgery will decrease the intensity of post-operative pain following total knee replacement.

Timeline

Start
2007-05
Primary completion
2008-12
Completion
2008-12

Outcome

Missed primary endpoint

paper There were no statistically significant differences between the pregabalin and placebo groups with respect to the primary endpoint in any of the three trials. PMID 25565885 ↗

registry Pregabalin (300 mg) vs Placebo; p = 0.3619; Mean Difference (Final Values) -0.339 (95% CI -1.070 to 0.392) NCT00442546 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 150 mg —
Subject Pregabalin Small molecule 300 mg —

Indications